KEY POINTS
- This prospective, single-arm phase I dose-escalation trial evaluated intravenous papaverine as a hypoxic tumor radiosensitizer in patients undergoing stereotactic body radiotherapy for early-stage non-small cell lung cancer or limited pulmonary metastases. Between June 2019 and October 2025, 19 patients were enrolled and 18 completed treatment, with a median follow-up of 33.4 months. The cohort included primary lung cancers and metastases from renal cell, head and neck, colorectal, uterine, and ovarian malignancies.
- The strategy aimed to reduce tumor oxygen consumption rather than increase oxygen delivery. Papaverine inhibits mitochondrial electron transport chain complex I, potentially increasing oxygen availability in hypoxic tumor regions and enhancing radiation-induced DNA damage. Patients received intravenous papaverine 30–90 minutes before each SBRT fraction, with 50 Gy in four or five fractions delivered using VMAT. The Bayesian optimal interval design evaluated doses of 0.5, 1.0, and 2.0 mg/kg, with a target dose-limiting toxicity rate of 25%.
- The selected maximum tolerated dose was 2.0 mg/kg, the highest dose administered in the trial. Two patients received 0.5 mg/kg, ten received 1.0 mg/kg, and six received 2.0 mg/kg. At 2.0 mg/kg, the posterior estimated dose-limiting toxicity probability was 17% (95% credible interval 1–53%). A higher planned dose level of 3.0 mg/kg was not tested, meaning that the trial established tolerability at 2.0 mg/kg rather than demonstrating that higher doses would necessarily be unsafe.
- Two dose-limiting toxicities occurred, including grade 3 pneumonia in a patient receiving 1.0 mg/kg and grade 3 fatigue in a patient receiving 2.0 mg/kg. Other frequently reported adverse events included dizziness, fatigue, flushing, hypertension, and nausea, generally transient and associated with infusion. Reducing the intravenous infusion rate from 30 to 15 mg/min improved tolerability. Operational feasibility was demonstrated by delivering 89% of 76 treatment fractions within 90 minutes after papaverine infusion.
- Estimated two-year primary tumor control was 100%, with only one local recurrence, occurring at 38.1 months. Among 18 evaluable patients, complete response occurred in 4 (22%), partial response in 6 (33%), and stable disease in 8 (44%), yielding an objective response rate of 55.6%. Estimated two-year regional and distant control were 93.8% and 81.6%, respectively. However, without an SBRT-alone comparator, these favorable results cannot establish that papaverine improved tumor radiosensitivity or local control.
- Two-year progression-free survival was 62.8%, with median PFS of 33.4 months (95% CI 12.4 months to not reached). Estimated two-year overall survival was 81.3%, and median OS was not reached. Exploratory analysis suggested better two-year PFS in early-stage NSCLC than in metastatic disease (83.3% vs 50.5%), but the comparison was descriptive and the heterogeneous cohort was too small to support meaningful efficacy conclusions.
- An optional BOLD-MRI substudy provided preliminary evidence of altered tumor oxygenation, but only one patient contributed the reported imaging analysis. Median tumor T2* increased from 6.0 ms before papaverine to 7.3 ms afterward while breathing room air, and the proportion of tumor voxels with T2* below 10 ms decreased from 80.8% to 67.9%. These changes are compatible with improved oxygenation but do not constitute definitive biological validation. The small imaging sample, absence of direct tissue oxygen measurements, and nonrandomized clinical design remain substantial limitations.
CLINICAL TAKEAWAY
Intravenous papaverine can be incorporated into lung SBRT at doses up to 2.0 mg/kg with manageable observed toxicity, providing an early clinical feasibility signal for mitochondrial inhibition as a hypoxia-targeting radiosensitization strategy. However, the excellent local control observed in this small phase I cohort cannot be attributed to papaverine without randomized comparison, and confirmation of tumor oxygenation changes remains necessary.
SOURCE
International Journal of Radiation Oncology, Biology, Physics